Document:

Exhibit
        4.2

      

       

      

      February
        28, 2006

      

      Omicron
        Master Trust

      650
        Fifth
        Avenue

      24th
        Floor

      New
        York,
        New York

      USA
        10019

      Attention:   Brian
        Daly

      

      

      Dear
        Sirs:

      
         

        
          	Re:	Generex Biotechnology
                  Corporation
	 	- Amendment to Jan
                  20 06
                  Additional Investment Right

        

         

        We
          make
          reference to the additional investment right issued by Generex Biotechnology
          Corporation (the “Company”)
          to
          Omicron Master Trust (“Omicron”)
          on
          January 20, 2006 pursuant to which the Company, inter
          alia,
          granted
          to Omicron the right to purchase a $1,000,000 principal amount debenture
          convertible at $1.25 per share (the “AIR”).

      

      

      The
        Initial Exercise Date (as that term is defined in the AIR) of the AIR is
        expressed therein as the 181st
        day
        after the date thereof. The Company hereby confirms that, in consideration
        of
        the exercise of the AIR by Omicron and the delivery to the Company of a Notice
        of Exercise in respect thereof on or before the close of business on February
        28, 2006, the Company has agreed to abridge the Initial Exercise Date and
        to
        honor the aforementioned Notice of Exercise.

      

      Yours
        truly,

      

      Generex
        Biotechnology Corporation

      

      /s/
        Mark
        A. Fletcher

      

      

      Mark
        A.
        Fletcher

      Executive
        Vice-President, General Counsel

      maf:hsExhibit
        4.3

      

       

      

      February
        28, 2006

      

      Iroquois
        Capital LP

      641
        Lexington Avenue

      26th
        Floor

      New
        York,
        New York

      USA
        10022

      Attention:   Joshua
        Silverman

      

      Dear
        Sirs:

      
         

        
          	Re:	Generex Biotechnology
                  Corporation
	 	- Amendment to Jan
                  20 06
                  Additional Investment Right

        

         

      

      We
        make
        reference to the additional investment right issued by Generex Biotechnology
        Corporation (the “Company”)
        to
        Iroquois Capital LP (“Iroquois”)
        on
        January 20, 2006 pursuant to which the Company, inter
        alia,
        granted
        to Iroquois the right to purchase a $1,000,000 principal amount debenture
        convertible at $1.25 per share (the “AIR”).

      

      The
        Initial Exercise Date (as that term is defined in the AIR) of the AIR is
        expressed therein as the 181st
        day
        after the date thereof. The Company hereby confirms that, in consideration
        of
        the exercise of the AIR by Iroquois and the delivery to the Company of a
        Notice
        of Exercise in respect thereof on or before the close of business on February
        28, 2006, the Company has agreed to abridge the Initial Exercise Date and
        to
        honor the aforementioned Notice of Exercise.

      

      Yours
        truly,

      

      Generex
        Biotechnology Corporation

      

      /s/
        Mark
        A. Fletcher

      

      

      Mark
        A.
        Fletcher

      Executive
        Vice-President, General Counsel

      maf:hsExhibit
        4.4

      

       

      February
        28, 2006

      

      Smithfield
        Fiduciary LLC

      c/o
        Highbridge Capital Management, LLC

      9
        West
        57th
        Street

      27th
        Floor

      New
        York,
        New York

      USA
        10019

      Attention:   Ari
        J. Storch / Adam J. Chill

      

      

      Dear
        Sirs:

      
         

        
          	Re:	Generex Biotechnology
                  Corporation
	 	- Amendment to Jan
                  20 06
                  Additional Investment Right

        

         

      

      We
        make
        reference to the additional investment right issued by Generex Biotechnology
        Corporation (the “Company”)
        to
        Smithfield Fiduciary LLC (“Smithfield”)
        on
        January 20, 2006 pursuant to which the Company, inter
        alia,
        granted
        to Smithfield the right to purchase a $1,000,000 principal amount debenture
        convertible at $1.25 per share (the “AIR”).

      

      The
        Initial Exercise Date (as that term is defined in the AIR) of the AIR is
        expressed therein as the 181st
        day
        after the date thereof. The Company hereby confirms that, in consideration
        of
        the exercise of the AIR by Smithfield and the delivery to the Company of
        a
        Notice of Exercise in respect thereof on or before the close of business
        on
        February 28, 2006, the Company has agreed to abridge the Initial Exercise
        Date
        and to honor the aforementioned Notice of Exercise.

      

      Yours
        truly,

      

      Generex
        Biotechnology Corporation

      

      /s/
        Mark
        A. Fletcher

      

      

      Mark
        A.
        Fletcher

      Executive
        Vice-President, General Counsel

      maf:hsSECURED
      PROMISSORY NOTE

    

    
      	
              $12,000.00

            	
              Los
                Angeles, California

            
	 	
              February
                23, 2006

            

    

    

    

    FOR
      VALUE
      RECEIVED, Patient Safety Technologies, Inc. (the “Maker”), a Delaware
      corporation with an office located at 1800 Century Park East, Suite 200, Los
      Angeles, CA 90067, hereby promises to pay to the order of Ault Glazer Bodnar
      Acquisition Fund LLC (the “Payee”), a Delaware limited liability company, the
      principal sum of twelve thousand dollars ($12,000.00) plus any accrued interest
      thereon in lawful money of the United States on April 23, 2006 (the “Maturity
      Date”).

    

    The
      following is a statement of the other terms and conditions to which this
      promissory note (the “Note”) is subject to:

    

    Maker
      further promises to pay interest on the unpaid principal balance hereof at
      the
      rate of seven percent (7%) per annum, such interest to be paid on the Maturity
      Date. Interest shall commence accruing on the issue date and shall be calculated
      on the basis of a 365-day year and actual days elapsed. In no event shall the
      interest charged hereunder exceed the maximum permitted under the laws of the
      State of California.
      At the
      option of Maker, payments of principal and interest hereunder may be made in
      lawful money of the United States of America or, in whole or in part, of
      like-kind exchange including without limitation shares of any securities owned
      by the Maker (“Common Stock”), which shall be valued at the closing price of the
      Common Stock on the day before the Maturity Date obtained from the respective
      exchange.

    

    The
      Maker
      shall have the right, at any time, to prepay without penalty, in whole or in
      part, the unpaid principal and interest due on this Note as of the date of
      such
      prepayment.

    

    The
      entire unpaid principal balance of this Note and interest accrued with respect
      thereto shall be immediately due and payable upon the occurrence of any of
      the
      following (each, an “Event of Default”):

    

    a.
       The
      Maker
      filing for relief under any bankruptcy law;

    

    b. The
      filing of a lien, the issuance of a levy or execution, or the seizure,
      attachment or garnishment, or the entry of judgment on or against Maker or
      any
      of Maker’s property which shall not be released, satisfied of record or bonded
      within twenty (20) days thereafter, except liens which exist as the date hereof
      or liens to which the Payee shall consent; 

    

    c. The
      Maker
      creates, incurs, assumes or suffers to exist any liability for borrowed money,
      except borrowings in existence or committed on the date hereof and indebtedness
      to trade creditors or financial institutions incurred in the ordinary course
      of
      business; or

    

    d. The
      Maker
      has failed to pay the principal and any accrued and unpaid interest on the
      Maturity Date.

     

    
      
         

      

      
        -1-

        
          

        

      

      
         

      

    

    

    The
      obligations under this Note shall be secured by certain collateral of Maker
      in
      accordance with the terms of a Security Agreement entered into on the date
      hereof. 

    

    All
      rights and remedies available to the Payee pursuant to the provisions of
      applicable law and otherwise are cumulative, not exclusive and enforceable
      alternatively, successively and/or concurrently after default by Maker pursuant
      to the provisions of this Note.

    

    The
      Maker
      waives demand, presentment, protest and notice of any kind and consents to
      the
      extension of time of payments, the release, surrender or substitution of any
      and
      all security or guarantees for the obligations evidenced hereby or other
      indulgence with respect to this Note, all without notice.

    

    This
      Note
      may not be changed, modified or terminated orally, but only by an agreement
      in
      writing, signed by the party to be charged. The Maker hereby authorizes the
      Payee to complete this Note and any particulars relating thereto according
      to
      the terms of the indebtedness evidenced hereby.

    

    In
      the
      event of any litigation with respect to the obligations evidenced by this Note,
      the Maker waives the right to a trial by jury and all rights of set-off and
      rights to interpose permissive counterclaims and cross-claims. In
      the
      event this Note shall be in default, and placed with an attorney for collection,
      then Maker agrees to pay all reasonable attorney fees and costs of collection
      of
      Payee. This
      Note
      shall be governed by and construed in accordance with the laws of the State
      of
      California and shall be binding upon the successors, assigns, heirs,
      administrators and executors of the Maker and inure to the benefit of the Payee,
      its successors, endorsees, assigns, heirs, administrators and
      executors.

    

    The
      Maker
      hereby irrevocably consents to the jurisdiction of the state and federal courts
      in Los Angeles County, California in connection with any action or proceeding
      arising out of or relating to this Note. If any term or provision of this Note
      shall be held invalid, illegal or unenforceable, the validity of all other
      terms
      and provisions hereof shall in no way be affected thereby.

     

    
      	 	 	 
	 	PATIENT
              SAFETY
              TECHNOLOGIES, INC.
	 
 	 
 	 
 
	 	By:  	/s/ Louis
              Glazer M.D.
	 	
              
Name:
              Dr. Louis Glazer
	 	Title:
              Chief Executive Officer and Chairman

     

    
      
         

      

      
        -2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}]]